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Glycemic Control in Diabetes: A Tale of
Three Studies
ZACHARY T. BLOOMGARDEN, MD
M
uch of the controversy at the
American Diabetes Association
Scientiﬁc Sessions, held 6–10
June 2008 in San Francisco, California,
pertained to questions raised about the
beneﬁts of intensive glycemic control by
three large clinical studies: the Action to
Control Cardiovascular Risk in Diabetes
(ACCORD) trial, the Action in Diabetes
and Vascular Disease (ADVANCE) trial,
and the Veterans’ Administration Diabe-
tes Trial (VADT). All three presented
somewhat negative study results.
ACCORD
David Goff (Winston-Salem, NC) dis-
cussed the ACCORD study design. The
goal of ACCORD was to determine
whether cardiovascular disease (CVD)
event rates could be reduced by inten-
sivelytreatingthreeimportantriskfactors
(hyperglycemia, dyslipidemia, and high
blood pressure) in a double 2  2 facto-
rial design. For glycemia, the question of
A1C 6 vs. 7–7.9% was addressed. Goff
reviewed previous studies that led to the
decision to aim for the low A1C target. In
the UK Prospective Diabetes Study
(UKPDS), insulin and sulfonylurea treat-
ment achieved a mean A1C level of 7%,
with 7.9% in a control group. The 16%
CVD reduction just missed statistical sig-
niﬁcance. Metformin treatment in this
study achieved a mean A1C level of 7.4%
with 8% in a control group, associated
with a signiﬁcant 39% CVD reduction.
(Goff did not mention that, compared
with sulfonylureas alone, the other
UKPDS metformin substudy showed that
metformin with a sulfonylurea was asso-
ciated with 96, 60, and 9% increases in
diabetes-related and all-cause mortality
and in myocardial infarction [1].) A non-
signiﬁcant CVD risk reduction of 50%
was seen in the Kumamoto study, while
there was also a nonsigniﬁcant CVD risk
increase of 50% in the Veterans’ Affairs
Cooperative Study on Glycemic Control
and Complications in Type II Diabetes
(VACSDM); both studies showed A1C
7.1% in the treatment group and 9.3–
9.4% in the control group. Analysis of a
number of observational studies suggests
thatforevery1%increaseinA1C,thereis
an 18% increase in the risk of CVD. The
ACCORDstudywasbasedonthehypoth-
esis that a 1.5% difference in A1C would
resultina15%differenceineventratesin
apopulationofhigh-riskdiabeticindivid-
uals having a 3% annual CVD event rate.
Power calculations required a sample size
of 10,000 individuals, with 10,251 actu-
ally participating and 5,128 randomized
to intensive and 5,123 to standard glyce-
mia goals. In addition, half of the partici-
pantswererandomizedtointensiveblood
pressure lowering to a systolic goal 120
mmHg (2,362 individuals) vs.  140
mmHg (2,371 individuals), and half were
randomized to statin plus ﬁbrate (2,753
individuals)vs.statinplusplacebo(2,765
individuals). Eligibility required stable
type 2 diabetes treatment for at least 3
months with A1C 7.5–9.0%, BMI 45
kg/m
2, creatinine 1.5 mg/dl, and age
40–79 years with, or 55–79 years with-
out, established CVD—the latter group
either having other anatomic evidence of
atherosclerosis, albuminuria, left ventric-
ularhypertrophy,oratleasttwoCVDrisk
factors.
Theprimaryoutcomewasﬁrstoccur-
rence of nonfatal myocardial infarction,
nonfatal stroke, or cardiovascular death,
and secondary outcomes included the
above individual outcomes, total mortal-
ity, quality of life, cost, cognitive health,
skeletal health, and microvascular out-
comes. At baseline, the groups were well
matched, with median age 62 years, dia-
betes duration 10 years, just over one-
third of the subjects with a prior CVD
event, mean BMI 32 kg/m
2, blood pres-
sure 136/75 mmHg, A1C 8.3%, and LDL
cholesterol 105 mg/dl. Proportions of
subjectsundergoingdiabetestreatmentat
baseline were as follows: 35% were on
insulin, 60% on metformin, 19% on a
thiazolidinedione,and62%onastatin.At
baseline and during the trial, 85 and 91%
took a blood pressure–lowering medica-
tion, 53 and 70% an ACE inhibitor, 54
and 76% aspirin, and 29 and 48% a
-blocker.
HertzelGerstein(Hamilton,ON)pre-
sented the mortality and primary out-
come results. All randomized patients
were analyzed by intention to treat, with
25 in each group lost to follow-up and
justover300ineachgroupdiscontinuing
the intervention. The target was an essen-
tially normal A1C, stressing lifestyle as
well as comprehensive pharmacologic
treatment,withattentionpaidtohypogly-
cemia in all patients. In the intensive
group, A1C decreased from a median of
8.1 to 6.7% at 4 months, 6.5% at 8
months, and 6.3–6.4% from 1 year
through 6 years, while the A1C of the
standard-treatment group decreased to
7.5% at 4 months and remained at that
level for the duration of the study. Inten-
sive treatment was associated with signif-
icant excess in nonhypoglycemia serious
adverseeventsversusthenumberinthose
undergoing standard treatment (in 113
vs. 82 subjects, respectively), with signif-
icant excess in ﬂuid retention (3,541 vs.
3,378 participants) and with signiﬁcantly
less elevation in transaminase levels.
The glycemia comparison was
stopped by a 10-individual monitoring
board on 8 January 2008 after a 22%
increase in all-cause mortality was
found in 1.41% of intensively treated
patients versus 1.14% of standard-
treatmentpatients,withthecomparison
statisticallysigniﬁcantatP  0.04.CVD
mortality also increased, occurring 35%
more often in 2.63 vs. 1.83% of the re-
spectivegroupsoveramean3.5yearsof
observation (statistically signiﬁcant at
P  0.02). Interestingly, despite the ex-
tremely careful adjudication process, the
largest single category of deaths was one
termed “unexpected/presumed CVD,” af-
fecting 86 intensively treated vs. 67 stan-
dard-treatment patients (Table 1). The
attribution of the increase in mortality
among intensively treated individuals to
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therewasatthesametimeastatisticallysig-
niﬁcant (P  0.004) reduction in nonfatal
myocardial infarction occurring in 3.63 vs.
4.59% of patients randomized to intensive
versus standard treatment, respectively.
Subgroup analysis failed to show dif-
ferences between men and women or be-
tween nonwhite and white participants.
There were nonsigniﬁcant trends toward
a greater effect of intensive treatment on
mortality among individuals with versus
without prior CVD, with baseline A1C
8% (versus 8%), and with baseline
age 65 years (versus 65 years). The
primary outcome—ﬁrst occurrence of
nonfatal myocardial infarction, non-
fatal stroke, or cardiovascular death—
occurred signiﬁcantly less often in the in-
tensively treated subgroup without prior
CVD and less often among the subgroup
with baseline A1C 8%. Gerstein re-
garded these as hypothesis-generating
ﬁndings and stated that, although ongo-
ing follow-up and analysis will be impor-
tant, the conclusion of the study was that
“in people with type 2 diabetes at high
risk for CVD, with an A1C of 7.5% or
more, a therapeutic strategy that targets
an A1C 6% vs. 7–7.9% increases mor-
tality over 3.5 years.”
Robert P. Byington (Winston-Salem,
NC) discussed the relationship between
hypoglycemia and mortality outcome. In
attempting to identify causes and mecha-
nisms of the increased mortality, a num-
ber of exploratory analyses were carried
out. Severe hypoglycemia occurred in
three times as many intensive- as stan-
dard-treatment patients, with annual 3.3
vs. 1.1% rates, respectively. This, he
stated,wasanticipated,but“whatwasnot
expected was that [intensive treatment]
participants...would have a mortality
higher than the standard group.” He pre-
sented an analysis of the relationship
between mortality and severe hypoglyce-
mia, deﬁned by requirement for medical
or paramedical intervention, with docu-
mented glucose 50 mg/dl and relief by
parenteral or oral glucose or by glucagon.
Review of a glucose diary and speciﬁc
questioningaboutsuchepisodesofsevere
hypoglycemia were carried out at each
visit. Byington noted that stratiﬁcation by
a postrandomization characteristic such
as hypoglycemia is inherently con-
founded by treatment group assignment,
as it may be mediated by the intensive
strategy per se, and that ﬁndings of such
analyses should therefore be regarded as
hypothesis generating. Given this caveat,
he reported that 93% of patients did not
experience severe hypoglycemia and had
a mortality of 1.2% per year, while for the
705 participants who experienced at least
one episode of severe hypoglycemia, the
mortality was signiﬁcantly greater (3.1%
per year). Both among individuals ran-
domizedtointensivestrategy,with2.8vs.
1.2% respective annual mortality rates,
and in the standard-treatment group the
same association between hypoglycemia
and mortality was seen. Intriguingly,
among participants not experiencing se-
vere hypoglycemia, 223 vs. 186 deaths
occurred, representing a 24% increase,
which is similar to that found in the over-
all group. However, in those who did ex-
perience severe hypoglycemia, 34 vs. 17
deaths occurred, with annual mortality
rates (given the larger number of such pa-
tients among those assigned to intensive
treatment) of 2.8 vs. 4.8%. Intensive
treatment among those experiencing se-
vere hypoglycemia, then, was associated
with unadjusted risk of 0.4, and the
risk—adjusted by age, sex, race, educa-
tion, standard cardiovascular risk factors,
diabetes duration, A1C, creatinine, albu-
minuria, and other known or presumed
mortality predictors—in the intensively
treated group was 0.52 as great as that in
the standard-treatment group. The differ-
ence between the overall 1.22-fold mor-
talityandthe0.52-foldadjustedmortality
ratio in the group experiencing severe hy-
poglycemia was statistically signiﬁcant.
Repeatingtheanalysiswithabroaderdef-
inition of severe hypoglycemia to include
any assistance by another individual did
not change the conclusion. Byington ac-
knowledged, however, that there was no
systematic analysis or collection of low
glucose levels other than that of severe
hypoglycemia as deﬁned above, such that
although the investigators concluded that
severe hypoglycemia was not related to
the higher mortality, full assessment of
the relationship between hypoglycemia
and the outcome of ACCORD may not be
possible.
Michael E. Miller (Winston-Salem,
NC) discussed the relationship between
prescribed medications and mortality in
ACCORD. He pointed out that partici-
pants were not randomized to different
medications, and the choice of medica-
tion in a given participant was based on
clinical judgment and characteristics of
participants.Adjustmentforpatientchar-
acteristics may, he stated, not be able to
distinguish between treatment assign-
ment and an actual medication effect.
Analysis including self-reported adher-
ence has not yet been carried out. The
main medication differences between the
intensive-andstandard-treatmentgroups
were in the former making greater use of
repaglinide, rosiglitazone, and basal and
bolus insulin and in the latter making
greater use of premixed insulin, both in
percentage ever prescribed and in the
time of use of the medication. Insulin was
given more often to those with prior CVD
or longer duration of diabetes, while ro-
siglitazonewasgivenlessoftentopatients
with baseline history of CVD. Exenatide
was less likely to be given to participants
using insulin, and both rosiglitazone and
exenatide were given 25% less often to
the 23% of participants with diabetes du-
ration 15 years. Taking medication use
into account and adjusting for baseline
Table 1—Causes of death in the ACCORD trial
Cause of death
Intensive-treatment
group
Standard-treatment
group
Unexpected/presumed CVD 86 67
Myocardial infarction 19 13
Congestive heart failure 23 16
Cardiovascular procedure 10 3
Arrhythmia 4 10
Noncardiovascular procedure 1 3
Stroke 9 11
Other CVD 8 10
Cancer 65 63
Non-cancer/CVD 50 35
Indeterminate 7 11
Total 282 242
Data are n. Data available from http://diabetesconnect.org/storetemplate/webcast_viewer/preview/aspx?
type0&lid3934. Accessed 6 July 2008.
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mortality ratio decreased from 1.22 to
1.19, which are similar ﬁgures but no
longer statistically signiﬁcant at the 95%
conﬁdence level. When addressing in
particular the use of rosiglitazone in com-
bination with insulin, the investigators
found no evidence of adverse effect on
mortality. Exenatide was associated with
lower mortality but was not used fre-
quently in the study, and both premixed
and bolus insulin types were associated
with greater mortality; however, pre-
mixed insulin was more used in the stan-
dard-treatment group and bolus insulin
in the intensive-treatment group.
Jeffrey L. Probstﬁeld (Seattle, WA)
discussedthebloodpressureandlipidtri-
als. Hypertension and dyslipidemia are
more common in diabetes and associated
with disproportionate increase in CVD
risk,withthecombinationmultiplicative,
but optimal treatment approaches have
not been determined. The blood pressure
study will have a 94% power to detect a
20% effect on outcome, and the lipid
study will have an 87% power to detect
such an effect; both of these trials con-
tinue and will complete in 2009, with re-
portinganticipatedin2010.Therewasno
interaction of blood pressure or of lipid
treatment with the adverse glycemia-
treatment effect.
Denise Simons-Morton (Bethesda,
MD) summarized the ACCORD ﬁndings,
emphasizing that because the study was a
strategy trial, speciﬁc treatment and pa-
tient characteristics may be difﬁcult to re-
late to outcomes. The suggestions of
reduced major cardiovascular events in
the primary prevention group and among
those with A1C 8% at baseline, she
stated, may hint at important directions
for further study, and ongoing analyses
will include the microvascular outcome
study, comparisons of outcomes, such as
those in ECG abnormality and microvas-
cular disease, of outcomes among those
with lesser or greater change in body
weight, creatinine, or edema. Epidemio-
logic analyses of the relationship between
A1C and outcomes and the effects of spe-
ciﬁc medications on A1C and on out-
comes are planned. At the present time,
however, she stated, “maximum lowering
of glycemia using an ACCORD-like strat-
egy in ACCORD-like patients is not war-
ranted because of undue risk.”
ADVANCE
ADVANCE was a randomized controlled
factorial trial of 11,140 patients with type
2 diabetes randomized to intensive blood
pressureandglycemictreatment.Stephen
MacMahon (Sydney, Australia) stated
thatthiswasanindependentinvestigator-
initiated trial sponsored by the National
Health and Medical Research Council of
Australia and by Servier, with the spon-
sors not participating in any of the edito-
rial committees, involving some 200
collaborating sites from 20 countries, in-
cluding Canada, Australia, China, Russia,
and India. The study aim was to deter-
mine the effects of intensive glucose con-
trol (A1C 6.5) and blood pressure–
lowering with an ACE inhibitor plus a
diuretic on macro- and microvascular
outcomes. The UKPDS showed a 12% re-
duction in total diabetes-related end
points, primarily microvascular, without
a clear reduction in myocardial infarction
or stroke, although a relationship could
be shown between the achieved level of
A1Cduringfollow-upandmacrovascular
disease. The UKPDS in essence compared
A1C of 8 vs. 7%, but, McMahon stated,
“theguidelineshavegonebeyondtheran-
domized evidence...using epidemio-
logicdata.”Thequestion,then,iswhether
achievinganA1Clevel6.5–7%actually
provides additional protection for either
micro- or macrovascular disease. The
UKPDSalsoshowedthattightbloodpres-
surecontrolreduceddiabetes-relatedend
points by 25%, with epidemiologic
analysisshowingacontinuouseffectupto
a systolic blood pressure of 115 mmHg,
but again the study actually compared
systolic blood pressure levels of 155 vs.
145 mmHg, although guidelines have
extrapolated from these ﬁndings to sug-
gest beneﬁt of further blood pressure
lowering. A second question, then, is
whether lowering systolic blood pres-
sure to 130–135 mmHg produces ad-
ditional protection for either micro- or
macrovascular outcomes.
The glucose component of the AD-
VANCE study was based on an extended-
releaseformofthesulfonylureagliclazide,
and the blood pressure component used
thecombinationofperindoprilwithinda-
pamide. Glucose treatment involved fre-
quent visits and A1C monitoring, with
drug titration beginning with gliclazide,
then adding other orals including met-
formin, then adding long-acting insulin,
andﬁnallyaddingpreprandialinsulinbo-
lus treatment. Rather than employing
forced titration, the advancement of gly-
cemic treatment was determined by the
local study trial coordinator. Primary
study outcomes were nonfatal stroke,
nonfatal myocardial infarction, or death
from any cardiovascular cause (including
sudden death and microvascular out-
comes of new or worsening nephropathy,
based on increased albuminuria, dou-
bling of creatinine, development of pro-
liferative retinopathy, macular edema,
blindness, or need for photocoagulation).
Sample size was calculated from an antic-
ipated 1% A1C and 6 mmHg blood pres-
sure reductions, both of which were
assumed to decrease micro- and macro-
vasculareventsby16%fromexpected3%
annual incidences. Most patients were re-
cruited in 2002, with one-half from Eu-
rope and one-third from China. Mean age
was 66 years, 43% were women, diabetes
duration averaged 8 years, one-third of
subjects had a history of macrovascular
disease and one-tenth of microvascular
disease, and 28% had microalbuminuria.
Baseline blood pressure was 145/81
mmHg, fasting blood glucose (FBG) 153
mg/dl, and A1C 7.5%.
John Chalmers (Sydney, Australia)
presented the blood pressure results. Pa-
tients in the intensive blood pressure–
lowering arm were treated with 2 mg
perindopril plus 0.625 mg indapamide
for 3 months, with the dose doubled
subsequently. At baseline, ACE inhibi-
tors were used by 40% and aspirin by
50% of the participants. At 4.3 years,
73% of patients adhered to treatment.
Systolic blood pressure was lowered by
5.6 mmHg, and diastolic blood pressure
was lowered by 2.2 mmHg, with the con-
trol versus intervention groups having
levels of 140/77 vs. 135/75 mmHg. Mor-
tality decreased by 14%, with an 18% re-
duction in cardiovascular mortality.
There was a 9% reduction in the macro-
and microvascular composite end point.
Coronary outcomes decreased by 14%,
and renal outcomes decreased by 21%,
driven by a reduction in new-onset mi-
croalbuminuria. Albuminuria progres-
siondecreasedby22%andalbuminuria
regression increased by 16% with the
perindopril/indapamide combination.
There was no relationship of renal out-
come to baseline blood pressure, age,
sex, diabetes duration, or other blood
pressure–lowering treatment, and epide-
miologic analysis showed a linear rela-
tionship of renal disease reduction to a
systolicbloodpressureof106mmHg,im-
plying, Chalmers stated, that “there’s no
lower threshold.” There was no signiﬁ-
cant change in cerebrovascular disease
or clinical retinopathy events; retinal
photograph analysis has not been com-
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dopril/indapamide prevented one
major vascular event for every 66, one
deathforevery79,and1coronaryevent
for every 75 treated participants, which
is important given what would typically
be considered adequate existing blood
pressure treatment in the majority of
patients, with 65% of the placebo group
receiving aspirin. Chalmers suggested
that “in some respects present [existing]
guidelines may even be conservative.”
Anushka Patel (Sydney, Australia)
discussed the glucose control compari-
son. The intensive–glucose control arm
used gliclazide MR in all participants,
with unrestricted additional therapy to
achieve target A1C 6.5%, while in the
standard arm a sulfonylurea other than
gliclazide was used. All treatment assign-
ment was at the discretion of the treating
physician. The intensive–glucose treat-
mentgrouphadmorefrequentvisits,em-
phasizing lifestyle, with drug titration
based on A1C and FBG. At the time of
randomization, 71% of patients received
a sulfonylurea, 61% metformin, 4% a
thiazolidinedione, 8% acarbose, and few
were treated with a glinide or insulin.
During the study, 40% of intensive treat-
ment–group participants were treated
with insulin, 74% with metformin, 17%
with a thiazolidinedione, and 91% (by
trial design) with a sulfonylurea, exceed-
ingthetreatmentgiventhecontrolgroup.
A1C levels decreased from 7.5% (median
7.2) at onset to 7.3% (7.0) vs. 6.5% (6.4)
in the control versus intensive groups, re-
spectively, with the greatest decrease oc-
curring during the initial 6 months. The
average difference over the course of the
trial was 0.7%, which is less than the 1%
difference in the trial design. FBG de-
creased from 153 to 139 mg/dl in the
standard-treatment group and to 112
mg/dl in the intensive-treatment group.
At study conclusion, 21 and 44% of pa-
tients, respectively, had A1C 6–6.5%,
and 8 vs. 20% had A1C 6%; i.e., the
goal of extending the achieved A1C
from the 7% mean level in UKPDS was
achieved. Combined macro- and micro-
vascular end points decreased 10%,
without signiﬁcant reduction in total
macrovasculardisease,nonfatalstroke,or
myocardialinfarction,althoughtherewas
a trend toward reduction in cardiovascu-
lar mortality. Microvascular events de-
creased by 14%, with a 21% reduction in
new or worsening nephropathy, perhaps
in part related to a 1.6-mmHg lower sys-
tolic blood pressure with intensive glyce-
mic treatment, which might be explained
by the closer follow-up of this group.
Heart failure, peripheral arterial disease,
cognitive function, and neuropathy did
not change. There was no heterogeneity
across baseline A1C or FBG groups and
no evidence of subgroups showing in-
creased mortality.
Bruce Neal (Sydney, Australia) dis-
cussed the occurrence of hypoglycemia,
deﬁned as glucose 50 mg/dl and/or an
episode with typical symptoms and signs.
Hypoglycemia was considered severe if
the individual required assistance or mi-
nor if the episode was self-treated, with
the two forms occurring in 231 and
4,500 individuals, respectively, at rates
of0.56and105episodesper100patient-
years. Severe and minor hypoglycemia
occurred 86 and 41% more often with
intensive glycemic treatment. There was
one fatal hypoglycemic episode in the
standard-treatment group and one epi-
sode leading to permanent disability each
in the standard- and intensive-treatment
groups. The Mini Mental State Examina-
tionshowedgreaterdecreaseamongindi-
viduals who had severe hypoglycemia,
although this was quantitatively modest,
and there was no evidence of adverse
long-term sequellae.
Hospitalization occurred 7% more
often with intensive treatment, in 2,146
vs. 2,039 individuals, leading to 5,645
vs. 5,039 total hospitalizations. It does
not appear that the increase in hospital-
ization was related to hypoglycemia be-
cause this explained only 4% of the
excessinhospitalization,and,similarly,
initiationofinsulintreatmentexplained
only 2% of excess hospitalization.
Closer patient follow-up or a broad-
based adverse effect of intensive insulin
treatment is possible, with Neal noting
that the excess hospitalization com-
prised a broad range of categories, sug-
gesting that “the possibility that the
excess hospitalization ...[ w a s ]s i m p l y
due to the fact that...t h epatients were
seen more often.” Body weight was sta-
ble in the intensive group while de-
creasing in the standard group, leading
at 5 years to a 1.5-lb difference; weight
gain was less in Asian than in non-Asian
trial participants. Neal suggested that
the longer duration of diabetes may ex-
plain the relative weight stability be-
cause in the UKPDS most of the mean
6.8-lb weight gain with intensive treat-
ment was seen in the ﬁrst few years after
diagnosis. “Intensive glucose lowering
was clearly safe,” Neal concluded, not
increasing mortality or causing weight
gain and causing one severe hypoglyce-
mic episode per 81 individuals but pre-
venting one micro- or macrovascular
event per 52 patients.
Mark Cooper (Melbourne, Australia)
put the trial results in context, further ex-
ploring the question of beneﬁt versus
harm, the signiﬁcance of the renal ﬁnd-
ings, and the trial’s clinical implications.
There was beneﬁt in the primary out-
come,withparticularreductioninmicro-
vascular disease. No “J curve” increase in
adverseeffectoccurredatlowbloodpres-
sureorglucoselevels,withnoevidenceof
a major issue related to hypoglycemia.
The results of both the glucose and blood
pressure interventions led Cooper to
comment that “clearly this strategy is as-
sociated with a signiﬁcant reduction in
thedevelopmentandprogressionofrenal
disease.” Macroalbuminuria was closely
linked to CVD, with trial participants
with macroalbuminuria having a fourfold
increase in cardiovascular mortality. This
suggests that the renal beneﬁt would lead
tocardiovascularbeneﬁtovertime,which
is a long-term effect that the trial was not
designed to study. The renal impact of
glycemic treatment is impressive, with a
comment made in discussion after Coo-
per’s presentation that “5 years is normal
for a trial but a short piece of the whole
life.”
The UKPDS studied patients at the
time of diagnosis of diabetes who were on
average 10 years younger than those in
ADVANCE, with lower blood pressure
and lower baseline A1C. UKPDS, AD-
VANCE, and ACCORD had rather differ-
ent patient populations, with ACCORD
including many more patients receiving
insulin at baseline and patients from dif-
ferent geographic areas. ACE inhibitors
and statins are now more widely used
than when the ADVANCE and ACCORD
studies were designed. All-cause mortal-
ity was 1.8% in the UKPDS and 1.8% in
ADVANCE but 1.2% in ACCORD, which
Cooperspeculatedmightberelatedtothe
lower baseline blood pressure in AC-
CORD. In both the ADVANCE and
UKPDS studies, there was a nonsigniﬁ-
cantmean7%reductioninmortalitywith
intensive treatment, but in the ACCORD
study there was a 22% increase in mortal-
ity, although with signiﬁcant heterogene-
ity between subgroups. BMI and A1C
were higher in ACCORD, although none
of these factors clearly explain the differ-
ences between the mortality ﬁndings.
Cooper wondered whether the rate of re-
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ACCORD, compared with the gradual re-
duction in ADVANCE, and pointed out
that both studies may be contrasted with
UKPDS in showing no tendency for A1C
to subsequently rise. There was more use
of insulin and thiazolidinediones in AC-
CORD and of sulfonylureas and met-
formin in ADVANCE, and Cooper stated
that“thedifferenceinthewayglucosewas
reduced...could be a factor...b u tthis
has to be considered speculative.” Cer-
tainly, multifactorial intervention is re-
quired for individuals with diabetes, with
beneﬁt of blood pressure reduction in
ADVANCE and with statins well recog-
nized to be of beneﬁt in macrovascular
disease reduction. Although there was no
reduction in all-cause mortality in AD-
VANCE, there was signiﬁcant reduction
in renal events, which may predict subse-
quent reduction in macrovascular dis-
ease. In STENO-2, Cooper stated, there
wasnosigniﬁcantchangeinmortalityat4
and 8 years, so “we cannot exclude that
ACCORD...couldultimatelytranslateto
additional beneﬁts.” Eighty percent of the
intensive-treatment participants in AD-
VANCE achieved A1C 7%, and two-
thirds achieved A1C 6.5%, leading
Cooper to conclude that “we can achieve
an A1C of 6.5% gradually, using a
rather pragmatic approach which was
not associated with adverse effects of
weight gain...o rm ortality.” An inter-
esting implication of the study pointed
out in discussion is that sulfonylureas
may be safer and more effective than gen-
erally recognized, such that it may be ap-
propriate to compare different agents in
trials to those in “the next generation of
studies.”
The VADT
Carlos Abraira (Miami, FL) discussed the
VADTbackgroundanddesign.Inthepre-
liminary feasibility trial, A1C was 9.2% in
control subjects vs. 7.1% in those under-
going intensive glycemic treatment, but
thelattergrouphadanincreaseinadverse
outcomes. Three glycemic treatment
studies were available at that time: the
DCCT,showingreductioninmicrovascu-
lar complications with intensive treat-
ment of type 1 diabetes; the Kumamoto
study showing this as well in lean, rela-
tively young type 2 diabetic patients re-
ceiving insulin; and the UKPDS in type 2
diabetes, with reduction in photocoagu-
lation and cataract extraction but without
signiﬁcant reduction in cardiovascular
complications. In the UKPDS, however,
there was progressive worsening of glyce-
mic control regardless of glycemic regi-
men, with both the control and intensive-
treatment groups spending more time
above than below the 7.5–8% level,
which may be required for improvement
in CVD. Blood pressure treatment ap-
peared more than twice as potent as glu-
cose treatment in reducing adverse
outcome in this study. The Veterans’ Ad-
ministration investigators designed the
VADT as a randomized controlled trial of
1,791 type 2 diabetic individuals with
identical treatment for blood pressure,
lipids, and lifestyle factors and with the
primary outcome a composite of cardio-
vascular death, myocardial infarction,
stroke, congestive heart failure, severe in-
operable coronary artery disease, ampu-
tation for ischemia, and interventions for
coronary and peripheral arterial disease.
Retinopathy, nephropathy, and neuropa-
thy outcomes are still being analyzed. El-
igible patients had A1C 7.5%, were
either already receiving insulin or on a
maximal oral agent regimen, were aged
41 years, and had no major cardiovas-
cular events during the 6 months before
enrollment. Median follow-up was 6
years, with the study carried out from 1
Dececember 2000 to 31 May 2008. The
basic treatment scheme utilized rosiglita-
zone with either metformin or glime-
piride in all participants and insulin and
otheroralagentsasrequired.Atstudyon-
set,meanagewas60years,BMI31kg/m
2,
diabetes duration 12 years, and A1C
9.4%. Seventeen percent of subjects
smoked cigarettes, and 55% were former
smokers, and 97% of participants were
malebecauseofthegeneralmakeupofthe
Veterans’ Administration population.
Blood pressure was 132/76 mmHg, with
80% receiving blood pressure treatment.
Forty percent of participants had prior
vascular events, 43% had neuropathy,
and62%hadretinopathy(proliferativein
6%).
Glycemic control was stable at 8.4 vs.
6.9% in the control and intervention
groups, respectively. During the study,
8.5% of patients withdrew: 4.3% of
whom did so during the ﬁrst year and
10% of whom died. Insulin was given to
70 vs. 85% of the two groups. Rosiglita-
zoneandmetforminwereusedmorethan
glimepirideduringtheﬁrstyear,butthere
was similar use of all three during the
third through ﬁfth years. Insulin doses
graduallyincreasedto45vs.57units/day.
BMI increased in both groups, particu-
larly the intensive-treatment group, with
a plateau at 3 years.
Severe hypoglycemia occurred 0.04
vs. 0.12 times per patient per year in the
standard- and intensive-treatment groups,
respectively, and the total hypoglycemia
frequency was 4.24 vs. 15.29 times per pa-
tient per year. Aspirin and statin use, cig-
arette smoking, and blood pressure
control were identical, with blood pres-
sure decreasing from 132/77 to 125/69
mmHg and median LDL cholesterol de-
creasing from 105 to 73 mg/dl during the
course of the trial. HDL cholesterol in-
creased and triglyceride decreased simi-
larlyinbothgroupsduringthetrial.Itwas
feasible,then,toachieveAmericanDiabe-
tes Association goals for A1C, blood pres-
sure, and LDL cholesterol in these
individuals with difﬁcult-to-control type
2 diabetes.
Thomas Moritz (Chicago, IL) dis-
cussedstatisticalmethodsandspeciﬁcally
addressed the impact of rosiglitazone.
The study assumed there would be a 21%
treatment difference at 6 years, with cu-
mulative survival rates of 40% inthestan-
dard- vs. 31.8% in the intensive-treatment
groups,togivestatisticalpowerof86%and
a two-sided  level of 5% for a sample size
of 1,700 participants. The ﬁnal sample
size of 1,791 individuals gave a power of
88% to detect such an effect. He noted
that a 42% increase in myocardial infarc-
tion with rosiglitazone has been reported
(2). In the VADT, only 5% of intensively
treated patients did not receive rosiglita-
zone; 16% received 4 mg and 79% re-
ceived 8 mg daily. On a per-visit basis,
rosiglitazone was not used on 32% of
standard- vs. 26% of intensive-treatment
visits;40vs.10%,respectively,received4
mg, and 27 vs. 65% received 8 mg. The
VADT studied relationships between ros-
iglitazone and time to ﬁrst myocardial in-
farction, time to cardiovascular death,
time to either, and time to new or wors-
ening congestive heart failure. In a case-
control analysis, 140 patients had
myocardial infarction, with two control
subjects used per case and matched for
baselineuseofinsulin,priormacrovascu-
lar events, duration in study, age within
4.35 years, and total cholesterol within
23.5mg/dl(one-halfSD).Smoking,statin
use, and HDL cholesterol levels were
somewhat discordant between case and
control subjects, but overall the matching
wassatisfactory.Moritzreportedthatros-
iglitazonewasactuallyusedmoreoftenin
the control group than among the case
subjects in association with both myocar-
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thus, not only was there no evidence of
harm, but there was evidence that rosigli-
tazone actually decreased these events.
Rosiglitazone also was less often used in
individuals having congestive heart fail-
ure, suggesting a treatment choice phe-
nomenon. A further time-dependent
covariate analysis allowed for assessment
of the effects of variables that changed
overtimeandshoweda30%reductionin
myocardial infarction with rosiglitazone
at either 4- or 8-mg doses that remained
signiﬁcant for the 8-mg dose after adjust-
ment for baseline variables. For cardio-
vascular death, all comparisons showed a
reduction in risk of 70%, and the com-
bined myocardial infarction or cardiovas-
cular death end point was signiﬁcant for
all comparisons. Moritz concluded, “We
could not ﬁnd any evidence that rosiglita-
zone was harming our patients.”
PeterReaven(Phoenix,AZ)discussed
the relationships of coronary and abdom-
inal arterial calciﬁcation (CAC and AAC,
respectively) and other novel risk factors
to cardiovascular events. Vascular cal-
cium is a rapid noninvasive measure of
atherosclerosis burden closely associated
with CVD events (3). A recent meta-
analysis suggests that CAC is a predictor
of events in asymptomatic nondiabetic
cohorts. There are considerably fewer
dataindiabeticpatientsontheprognostic
valueofCACandAAC.IntheVADT,324
participants had CAC and AAC before
study entry and at study end. The 88 in-
dividuals having a Veterans’ Administra-
tion composite outcome event had longer
diabetes duration, higher A1C, and lower
HDL cholesterol. CAC Agatston scores of
0–10, 10–100, and 100–400 were each
seen in 20% of studied patients, and
40% of patients had a score exceeding
400 units, with event rates of 10, 15, 30,
and 45%, respectively, in the four catego-
ries and with a more rapid time-to-event
rate in the higher score groups. AAC was
not as strong a risk separator. Comparing
CAC scores 100 vs. 100, there was a
ﬁvefold increase in risk, while a history of
a prior event was associated with a 2.5-
fold increase in composite event risk. The
CAC score was independent of standard
cardiovascular risk factors and was an
even stronger risk factor than having a
priorevent.Furthermore,Reavenshowed
evidence that the effect of the treatment
assignment was modiﬁed by the baseline
CAC score: the participants with a base-
line CAC score 100 showed reduction
in cardiovascular events with intensive
glycemic treatment, while glycemic treat-
mentwasnotassociatedwithreductionin
cardiovascular events in those with a
baseline CAC score 100.
William Duckworth (Phoenix, AZ)
discussed the effect of the glycemic con-
trol treatment group on cardiovascular
outcomes. He emphasized that the study
enrolled “the toughest patients we could
ﬁnd” and that to focus on glucose effects
theyendeavoredtoachieveexcellentcon-
trol of other cardiovascular risk factors.
The median A1C was 8.4% in the control
group vs. 6.9% in the intensive glycemic
treatment group, both groups showing
signiﬁcant improvement in A1C from
baseline, but there was a nonsigniﬁcant
13% cardiovascular event reduction with
theintervention.Baselinepredictorswere
prior event, age, duration, blood pres-
sure,LDLcholesterol,notbeinginaneth-
nic minority group, and A1C. Based on
analysis after adjusting for baseline fac-
tors, there was minimal effect of the gly-
cemia-control intervention. Predictors of
a ﬁrst primary event with treatment were
age, duration, HDL cholesterol, and A1C
at the time of study, with severe hypogly-
cemia during the 3 months before the
event second in importance to having a
prior event as a risk factor.
Durationofdiabetesshowedaninter-
action with treatment in the intensive-
treatment group but not in the standard-
treatment group. There was an increasing
beneﬁt of the glycemia-control interven-
tion in association with shorter diabetes
duration and no beneﬁt with diabetes du-
ration of 12–16 years, and an adverse ef-
fect of intensive treatment was seen with
18 years duration of diabetes. The in-
tensively treated patients had fewer coro-
nary revascularizations. Predictors of
cardiovascular death were prior event,
age, A1C, and low HDL cholesterol.
Again, having a recent severe hypogly-
cemia episode was associated with a
fourfold increase in likelihood of car-
diovacular death. Predictors of total
mortality were prior event, age, ciga-
rette use, baseline A1C, and, only in the
standard-treatment group, hypoglyce-
mia. Severe hypoglycemia was seen in
20% of intensive-treatment vs. 8.8% of
standard-treatment participants. There
were 29 cardiovascular deaths in the
standard-treatment vs. 36 in the inten-
sive-treatment group, with sudden
death in 4 vs. 11 patients, respectively,
accounting for all of the excess mortal-
ity. Predictors of sudden death were a
prior macrovascular event, BMI, A1C at
baseline, weight gained during the
study, and low HDL cholesterol. Duck-
worth concluded that in the studied
population of older, difﬁcult-to-control
patients, cardiovascular risk factors and
glucose control could be improved and
the risk for cardiovascular events could
be reduced. Recent severe hypoglyce-
mia was a predictor of cardiovascular
death and of the primary outcome and,
in the standard-treatment group, of all-
cause mortality. Duration was a signiﬁ-
cant predictor of the primary end point
and showed a highly signiﬁcant interac-
tion with the treatment effect in the in-
tensive-treatment group, suggesting
that intensive treatment might be pro-
tective during the ﬁrst decade of diabe-
tes but that late intensive treatment in
the fashion used in the VADT might be
harmful.
Comparing the trials
Are there important similarities in the
three trials? A striking ﬁnding of all three
studies is the suggestion that a beneﬁcial
effect of the glycemia-control interven-
tion is more likely in association with less
disease duration. In the published report
of the ACCORD study, trial participants
entering with baseline A1C 8%, rather
than having an adverse effect of intensive
glycemic treatment on mortality, showed
asigniﬁcantreductionintheprimaryout-
come favoring such treatment (4). Simi-
larly, in the ADVANCE trial, the
combined micro- and macrovascular pri-
mary outcome beneﬁt of the glycemia-
control intervention was seen in
participants without a baseline history of
macrovascular disease (5), and the CAC
score and duration of diabetes ﬁndings in
the VADT, described above, point in the
same direction.
Theeffectofhypoglycemiaappearsto
be of great importance. In the ACCORD
study, although the investigators stated
that this was not a mediator of the in-
creased mortality associated with inten-
sive treatment, they did ﬁnd that
hypoglycemia was associated with in-
creased mortality and that the intensive
intervention was associated with in-
creased hypoglycemia, and they ac-
knowledged not having collected full
information pertaining to home glu-
cose-monitoring results. It is intriguing
in this regard that 19 of the 40 excess
deaths in ACCORD are in the “unexpect-
ed/presumed CVD” category. If future
analyses of ACCORD are able to more
fully take into account participants’ home
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ship between weight gain and mortality,
or show that mortality was associated
with a higher degree of hemoglobin gly-
cation for a given level of glycemia, it may
be possible to gain a fuller understanding
of these questions. Severe and nonsevere
hypoglycemia did occur more often with
intensive glycemic treatment in AD-
VANCE, although the investigators did
not report this to be associated with any
less beneﬁt of the intervention. It is note-
worthy that there was actually a trend to-
ward a reduction in cardiovascular
mortality in association with intensive
glycemic treatment in this study. The
VADT similarly reported that hypoglyce-
mia occurred more often in association
with intensive glycemic treatment and
was associated with adverse outcome.
This study found that the increase in
mortality in the intensive-treatment
group was accounted for by an increase
in sudden death, which, combined with
the strikingly similar ﬁnding of the AC-
CORD study, suggests this to be an area
requiring more attention to the poten-
tial adverse effects of glycemia-control
treatment. The development of potent
treatment approaches less likely to
cause hypoglycemia should continue to
be an important pharmacologic goal.
References
1. UK Prospective Diabetes Study (UKPDS)
Group: Effect of intensive blood-glucose
control with metformin on complications
in overweight patients with type 2 diabe-
tes (UKPDS 34). Lancet 352:854–865,
1998
2. Nissen SE, Wolski K: Effect of rosiglita-
zone on the risk of myocardial infarction
and death from cardiovascular causes.
N Engl J Med 356:2457–2471, 2007
3. Reaven PD, Sacks J, the Investigators for
the VADT: Coronary artery and abdomi-
nal aortic calciﬁcation are associated with
cardiovascular disease in type 2 diabetes.
Diabetologia 48:379–385, 2005
4. The Action to Control Cardiovascular
Risk in Diabetes Study Group, Gerstein
HC, Miller ME, Byington RP, Goff DC Jr,
BiggerJT,BuseJB,CushmanWC,Genuth
S, Ismail-Beigi F, Grimm RH Jr, Probst-
ﬁeld JL, Simons-Morton DG, Friedewald
WT: Effects of intensive glucose lowering
in type 2 diabetes. N Engl J Med
358:2545–2559, 2008
5. The ADVANCE Collaborative Group, Pa-
tel A, MacMahon S, Chalmers J, Neal B,
Billot L, Woodward M, Marre M, Cooper
M, Glasziou P, Grobbee D, Hamet P,
Harrap S, Heller S, Liu L, Mancia G, Mo-
gensen CE, Pan C, Poulter N, Rodgers A,
Williams B, Bompoint S, de Galan BE,
JoshiR,TravertF:Intensivebloodglucose
control and vascular outcomes in patients
with type 2 diabetes. N Engl J Med 358:
2560–2572, 2008
Bloomgarden
DIABETES CARE, VOLUME 31, NUMBER 9, SEPTEMBER 2008 1919